Table II.

Impaired modulation of Mcl-1 and phospho-Bad expression in response to TLR agonists, except for TLR9a

Mean Fluorescence Intensity
Mcl-1Phospho-Bad
ControlsPatientControlsPatient
PBS74.3 ± 2.176.7 ± 2.757.7 ± 2.059.3 ± 4.1
MALP-2 (TLR2/6)121.0 ± 3.8b77.7 ± 3.290.3 ± 2.6b59.7 ± 3.5
Pam3CSK4 (TLR1/2)117.7 ± 2.0b75.3 ± 3.889.0 ± 2.3b60.0 ± 4.0
LPS (TLR4)121.7 ± 5.2b77.3 ± 2.890.7 ± 3.2b62.7 ± 3.2
R-848 (TLR7/8)124.3 ± 3.4b77.7 ± 2.791.0 ± 5.5b62.3 ± 5.2
CpG-DNA (TLR9)123.7 ± 3.8b106.7 ± 4.7b90.3 ± 3.8b80.3 ± 2.7b
  • a Whole-blood samples were preincubated at 37°C in a water bath with gentle agitation for 2 h (Mcl-1 expression) or 1 h (phospho-Bad expression) with PBS or with TLR agonists as described in the legend of Table I. Mcl-1 and phospho-Bad content was then measured by flow cytometry on methanol-permeabilized cells as described in Materials and Methods. Results are expressed as mean ± SEM (n = 3; each experiment was performed with a different healthy control). Values obtained with an irrelevant Ab of the same isotype or with nonimmune serum were subtracted.

  • b Significantly different from samples incubated with PBS (p < 0.05).